Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.74 |
| ▸ | TP53 | P04637 | 2/20 | 0.74 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.74 |
| ▸ | TSHR | P16473 | 1/20 | 0.74 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.74 |
| ▸ | CDK9 | P50750 | 1/20 | 0.74 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.74 |
| ▸ | RAB9A | P51151 | 10/20 | 0.70 |
| ▸ | NPC1 | O15118 | 9/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.70 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.70 |
| ▸ | CASP3 | P42574 | 1/20 | 0.69 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.69 |
| ▸ | MAPT | P10636 | 3/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.69 |
| ▸ | CCR6 | P51684 | 1/20 | 0.69 |
| ▸ | MAOA | P21397 | 2/20 | 0.67 |
| ▸ | MAOB | P27338 | 2/20 | 0.67 |
| ▸ | MEN1 | O00255 | 1/20 | 0.66 |
| ▸ | HPGD | P15428 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9479690 | 0.94 | CASP3 (0.81) | SMN1; SMN2TP53EPHX1TSHREPHX2 | |
| SCHEMBL23069076 | 0.92 | NPC1 (0.65) | SMN1; SMN2TP53EPHX1TSHREPHX2 | |
| SCHEMBL1275920 | 0.91 | ALDH1A1 (0.70) | SMN1; SMN2TP53RAB9ANPC1KMT2A | |
| SCHEMBL13104425 | 0.89 | SAE1 (0.71) | SMN1; SMN2TP53EPHX1TSHREPHX2 | |
| SCHEMBL19500970 | 0.89 | NPC1 (0.80) | SMN1; SMN2RAB9ANPC1KMT2ATAAR1 | |
| SCHEMBL11059378 | 0.89 | SMN1; SMN2 (0.94) | SMN1; SMN2TP53EPHX1TSHREPHX2 | |
| SCHEMBL12711075 | 0.88 | RAB9A (0.77) | SMN1; SMN2TP53TSHRRAB9ANPC1 | |
| Diphenylurea SCHEMBL133103 | 0.86 | SMN1; SMN2 (1.00) | SMN1; SMN2TP53EPHX1TSHREPHX2 | |
| SCHEMBL21423373 | 0.85 | MAPT (0.67) | SMN1; SMN2TP53EPHX1TSHREPHX2 | |
| SCHEMBL12994776 | 0.85 | HPGD (0.65) | SMN1; SMN2EPHX1RAB9ANPC1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 155 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090239841-A1 | Diaryl Ureas as CB1 Antagonists | NEUROGEN CORPORATION | 2009-09-24 | — | — | US | claimed |
| EP-1804785-A2 | DIARYL UREAS AS CB1 ANTAGONISTS | NEUROGEN CORPORATION (US) | 2007-07-11 | — | — | EP | claimed |
| WO-2006049941-A2 | DIARYL UREAS AS CB1 ANTAGONISTS | NEUROGEN CORPORATION (US) | 2006-05-11 | — | — | WO | claimed |
| US-6630512-B2 | Antiinflammatory agents; autoimmune disease | BIOGEN, INC. | 2003-10-07 | — | — | US | claimed |
| US-6624152-B2 | Inhibition and prevention of cell adhesion and cell adhesion-mediated pathologies. This invention relates to pharmaceutical formulations comprising these compounds and methods of using them for inflammatory and autoimmune diseases | BIOGEN, INC. | 2003-09-23 | — | — | US | claimed |
| US-20030083267-A1 | Cell adhesion inhibitors | BIOGEN, INC., A MASSACHUSETTS CORPORATION | 2003-05-01 | — | — | US | claimed |
| US-20030018016-A1 | Cell adhesion inhibitors | BIOGEN IDEC MA, INC. | 2003-01-23 | — | — | US | claimed |
| EP-0805796-B1 | CELL ADHESION INHIBITORS | BIOGEN INC (US) | 2002-12-11 | — | — | EP | claimed |
| US-6376538-B1 | ANTIINFLAMMATORY AGENTS; AUTOIMMUNE DISEASES | BIOGEN, INC. | 2002-04-23 | — | — | US | claimed |
| US-6306840-B1 | ANTISTICKING AGENTS OF OLIGOPEPTIDES | BIOGEN, INC. | 2001-10-23 | — | — | US | claimed |
| EP-0805796-A1 | CELL ADHESION INHIBITORS | BIOGEN, INC. (US) | 1997-11-12 | — | — | EP | claimed |
| WO-1996022966-A1 | CELL ADHESION INHIBITORS | BIOGEN, INC. (US) | 1996-08-01 | — | — | WO | claimed |
| CN-120192629-A | Resin composition | 味之素株式会社 | 2025-06-24 | — | — | CN | disclosed |
| CN-120192630-A | Resin composition | 味之素株式会社 | 2025-06-24 | — | — | CN | disclosed |
| CN-120134737-A | Resin sheet with metal foil | 味之素株式会社 | 2025-06-13 | — | — | CN | disclosed |
| CN-120134736-A | Resin sheet with metal foil | 味之素株式会社 | 2025-06-13 | — | — | CN | disclosed |
| US-4565648-A | FOR PRODUCTION OF POLYURETHANES | BAYER AKTIENGESELLSCHAFT (DE) | 1986-01-21 | — | — | US | disclosed |
| EP-0083096-A2 | Production of urethane compounds | Asahi Kasei Kogyo Kabushiki Kaisha (JP) | 1983-07-06 | — | — | EP | disclosed |
| US-4052454-A | PROCESS FOR THE MANUFACTURE OF UREAS | ATLANTIC RICHFIELD COMPANY (US) | 1977-10-04 | — | — | US | disclosed |
| US-3936484-A | Production of isocyanates from substituted ureas | ATLANTIC RICHFIELD COMPANY (US) | 1976-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090239841-A1 | Diaryl Ureas as CB1 Antagonists | CNR1, CNR2, OPRL1 | SMN1; SMN2 4056/4885TP53 4802/4885EPHX1 1972/4885 |
| US-20030083267-A1 | Cell adhesion inhibitors | ICAM1, VCAM1, EPCAM | SMN1; SMN2 3410/4885TP53 3223/4885EPHX1 445/4885 |
| US-20030018016-A1 | Cell adhesion inhibitors | ICAM1, VCAM1, EPCAM | SMN1; SMN2 3410/4885TP53 3223/4885EPHX1 445/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.